Genentech is partnering with DualityBio on next-generation antibody-drug conjugates, with $45 million paid upfront and potential milestone payments exceeding $1 billion. The collaboration uses DualityBio’s DUPAC payload platform, designed to address resistance associated with topoisomerase I inhibitor-based ADCs. Under the agreement, DualityBio will conduct discovery and early-stage development through Phase I, while Genentech will assume responsibility for global clinical development and commercialization. The deal is structured around milestones spanning development, regulatory approval, and commercial targets, with tiered royalties expected on net sales. For the ADC field, the investment signals continued appetite for payload innovation aimed at improving activity in tumors that progress on existing ADC payload classes.